Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment.
Xin Ying ChuaYuek Ling ChaiWee Siong ChewJoyce R ChongHui Li AngPing XiangKaddy CamaraAmy R HowellFederico TortaMarkus R WenkSaima HilalNarayanaswamy VenketasubramanianChristopher P ChenDeron R HerrMitchell Kim Peng LaiPublished in: Alzheimer's research & therapy (2020)
Taken together, our data suggest that plasma d16:1 S1P may be useful as a diagnostic marker for VCI, while the d18:1 to d16:1 S1P ratio is an index of dysregulated S1P-mediated immunomodulation leading to chronic inflammation-associated neurodegeneration and cerebrovascular damage.